Key result
Radiation-induced vascular remodeling in the lungs shares mechanisms with pulmonary arterial hypertension, suggesting PAH treatments could potentially prevent or treat these cardiac side-effects.
Why the study?
Thoracic radiotherapy can deliver considerable radiation doses to heart and lung tissue, leading to pulmonary vascular remodeling and cardiac dysfunction that resemble pulmonary arterial hypertension, highlighting a need to explore potential translational interventions.
Answers are grounded in this paper and cite their sources.
Radiation-induced lung injury may contribute to cardiotoxicity through pulmonary vascular remodeling mechanisms similar to pulmonary arterial hypertension, offering potential new therapeutic targets.
Radiotherapy is part of the treatment for many thoracic cancers. During this treatment heart and lung tissue can often receive considerable doses of radiation. Doses to the heart can potentially lead to cardiac effects such as pericarditis and myocardial fibrosis. Common side effects after lung irradiation are pneumonitis and pulmonary fibrosis. It has also been shown that lung irradiation has effects on cardiac function. In a rat model lung irradiation caused remodeling of the pulmonary vasculature increasing resistance of the pulmonary vascular bed, leading to enhanced pulmonary artery pressure, right ventricle hypertrophy and reduced right ventricle performance. Even more pronounced effects are observed when both, lung and heart are irradiated. The effects observed after lung irradiation show striking similarities with symptoms of pulmonary arterial hypertension. In particular, the vascular remodeling in lung tissue seems to have similar underlying features. Here, we discuss the similarities and differences of vascular remodeling observed after thoracic irradiation compared to those in pulmonary arterial hypertension patients and research models. We will also assess how this knowledge of similarities could potentially be translated into interventions which would be beneficial for patients treated for thoracic tumors, where dose to lung tissue is often unavoidable.
No takes yet. Share an insight, caveat, or question.
Wiedemann et al. (2022) conducted a review in Radiation-induced cardiac side-effects and pulmonary arterial hypertension. Thoracic radiotherapy was evaluated. Radiation-induced vascular remodeling in the lungs shares mechanisms with pulmonary arterial hypertension, suggesting PAH treatments could potentially prevent or treat these cardiac side-effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: